Should You Forget Eli Lilly and Buy This Magnificent High-Yield Dividend Stock Instead?

2026-03-01 06:05:00 ET

Eli Lilly (NYSE: LLY) is growing very quickly right now thanks to Mounjaro and Zepbound, its two GLP-1 drugs, the latter of which is approved for weight loss. Mounjaro's sales rose 99% in 2025, and Zepbound's sales were up a shocking 175%.

But these two drugs accounted for almost all of Lilly's top-line growth last year. That's a problem in the making -- and why you might want to consider an out-of-favor alternative like high-yielding Pfizer (NYSE: PFE) .

Image source: Getty Images.

Continue reading